Kinomica

Executive Summary

Kinomica is a UK-based diagnostics company founded in 2015, specializing in phosphoproteomics to advance precision oncology. Its proprietary platform, KScan®, analyzes tumor protein phosphorylation patterns to map activated signaling pathways, enabling clinicians to select optimal therapies and identify repurposing opportunities from existing drugs. By targeting the functional state of cancer cells rather than static genomic mutations, KScan® addresses the dynamic nature of tumor signaling, potentially improving treatment outcomes and reducing trial-and-error prescribing. The company positions itself at the intersection of functional proteomics and precision medicine, aiming to differentiate from genomic-only approaches. While still in development, Kinomica's technology holds promise for broadening therapeutic options, especially for patients with limited standard-of-care choices. The company operates in the competitive diagnostics landscape, but its focus on phosphoproteomics—a less saturated area—could offer a niche advantage if validated in clinical settings. Currently, Kinomica remains privately held with no disclosed funding rounds or regulatory approvals, suggesting an earlier stage of commercialization. Further clinical evidence and partnerships will be critical to establishing KScan®'s clinical utility and market adoption.